SCHEMBL3327780

SCHEMBL3327780

CC(C)(C)[C@@]1([C@H](O)c2cccc(F)c2)CN(C(=O)O)CCO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
USP2 O75604 3/20 0.38
CYP3A4 P08684 3/20 0.38
GRM5 P41594 1/20 0.38
DPP4 P27487 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
MTOR P42345 1/20 0.37
CYP2D6 P10635 4/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
TSHR P16473 2/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
TP53 P04637 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
RIPK1 Q13546 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3325335 1.00 ALDH1A1 (0.38) ALDH1A1USP2CYP3A4GRM5DPP4
SCHEMBL5705729 0.87 PKM (0.39) ALDH1A1CYP3A4DPP4DPP7CYP2D6
SCHEMBL3329277 0.87 SMN1; SMN2 (0.43) ALDH1A1USP2CYP3A4CYP2D6CYP1A2
SCHEMBL3332875 0.87 SMN1; SMN2 (0.43) ALDH1A1USP2CYP3A4CYP2D6CYP1A2
SCHEMBL3328458 0.87 SMN1; SMN2 (0.43) ALDH1A1USP2CYP3A4CYP2D6CYP1A2
SCHEMBL26105486 0.78 SMN1; SMN2 (0.33) SMN1; SMN2
SCHEMBL25313968 0.75 SMN1; SMN2 (0.32) ALDH1A1SMN1; SMN2
SCHEMBL4941555 0.68 DPP4 (0.39) ALDH1A1USP2CYP3A4DPP4DPP7
SCHEMBL4941547 0.68 DPP4 (0.39) ALDH1A1USP2CYP3A4DPP4DPP7
SCHEMBL4941737 0.68 DPP4 (0.39) ALDH1A1USP2CYP3A4DPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137316-A1 Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof FISH PAUL VINCENT 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137316-A1 Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof OPRL1, UGT1A1, HTR3B ALDH1A1 690/4885USP2 4583/4885CYP3A4 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.